Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia

SEATTLE & IRVINE, Calif.--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today announced the launch of the first of two pivotal Phase 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL™ PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. The initiation of the BRIO trials follows compelling topline data from the company’